Drew has 20 years of industry experience in clinical development across multiple therapeutic areas and phases of development, including oncology.
Prior to ElevateBio, Drew was Vice President, Global Development Team Lead for multiple Ultomiris rare disease development teams at Alexion Pharmaceuticals. While there, he also led the Nephrology Clinical Development subtherapeutic area. Under Drew’s leadership, Ultomiris was approved for the treatment of atypical hemolytic uremic syndrome in adult and pediatric patients, and late development programs were launched for additional indications in complement-mediated thrombotic microangiopathy and rare nephrology indications. Drew also made significant contributions to Soliris neuromyelitis optica spectrum disorder and Strensiq hypophosphatasia programs. Before Alexion, Drew spent 15 years at Merck, serving as a Clinical Lead and Development Team Lead for multiple early and late programs across therapeutic areas, including several Keytruda monotherapy and combination therapy programs, and Fosamax Vitamin D. In the Early Development space, Drew was responsible for approximately 15 first-in-human clinical trials.
Education & Accomplishments
Drew received his undergraduate degree in Molecular Biology from Princeton University, and his MD and PhD (Biochemistry and Molecular Biology) degrees from Thomas Jefferson University in Philadelphia, studying cartilage development and bone derived growth factors.
Interested in working with people like Drew? We’re looking for pioneers and innovative thinkers committed to developing the next-generation of cell and gene therapies. Review our open roles and find your future.